NCT04478305View on ClinicalTrials.gov

Affect of Duavive on Mood & Anxiety Symptoms

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 3, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
MenopauseDepression, AnxietySleepMenopause Related Conditions
Interventions
DRUG

Duavive 0.45Mg-20Mg Tablet

Duavee, marketed as Duavive in Canada.

Trial Locations (1)

L8P 3B7

RECRUITING

St Joseph's Healthcare, Hamilton

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

McMaster University

OTHER

collaborator

Pfizer

INDUSTRY

lead

St. Joseph's Healthcare Hamilton

OTHER

NCT04478305 - Affect of Duavive on Mood & Anxiety Symptoms | Biotech Hunter | Biotech Hunter